A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Non-small Cell Lung Cancer Clinical Trial

— REGOMUNE  

Official title:

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03475953
• Other study ID #: IB 2017-01
• Secondary ID: 2016-005175-27
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 4, 2018
• Est. completion date: December 31, 2025

Study information

• Verified date: March 2023
• Source: Institut Bergonié
• Contact: Sophie COUSIN, MD
• Phone: +33 5.56.33.33.33
• Email: s.cousin[@]bordeaux.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).

Assessement of the efficacy and safety of a low-dose of regorafenib (80mg/day) with avelumab in patients with advanced or metastatic colorectal tumors.

Description:

This is a multicenter, prospective open-labeled phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Regorafenib given in combination with Avelumab (no dose escalation for Avelumab) in patients with advanced digestive solid tumors followed by independent phase II trials to evaluate the association of Regorafenib at the RP2D with Avelumab in 17cohorts of advanced or metastatic tumors :

• Cohort A: Colorectal cancer not MSI-H or MMR-deficient

• Cohort B: GIST

• Cohort C: Oesophageal or gastric carcinoma

• Cohort D: Biliary tract cancer, hepatocellular carcinoma

• Cohort E: Soft-tissue sarcoma (STS)

• Cohort F: Radioiodine-refractory differentiated thyroid cancer (RR-DTC)

• Cohort G: Neuroendocrine gastroenteropancreatic tumors (GEP-NETs)

• Cohort H: Non-small cell lung cancer (NSCLC)

• Cohort I: Solid tumors (including soft-tissue sarcoma) with immune signature (TLS+).

In addition, to evaluate in a phase II trial, the association of a low-dose of regorafenib (80mg/day) with avelumab :

• Cohort A': colorectal not MSI-H or MMR-deficient (low dose)

• Cohort J: urothelial cancer

• cohort K: HPV-associated cancer with molecular confirmation p16 positive status

• cohort L: triple netagtive brest cancer

• cohort M: TMH-high solid tumors with status TMB-high already known

• cohort N: MSI-high solid tumors with status MSI-high already known

• cohort O: non clear-cell renal carcinoma

• cohort P: malignant pleural mesothelioma

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 747
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria :

1. Histology:

• Dose escalation part: histologically confirmed non MSI-H or deficient-MMR colorectal cancer, or GIST, or esophageal or gastric carcinoma or hepatobiliary cancers,

• Phase II trials : histologically confirmed

• non MSI-H or deficient-MMR colorectal cancer (cohort A),

• or GIST (cohort B). As recommended diagnosis by INCa, patients with GIST must have histologically confirmed by central review, except if it has been already confirmed by the RRePS Network

• or esophageal or gastric carcinoma (cohort C),

• or hepatobiliary cancers (cohort D),

• or soft-tissue sarcoma (STS) (cohort E). As recommended diagnosis by INCa, patients with STS must have histologically confirmed by central review, except if it has been already confirmed by the RRePS Network

• or radioiodine-refractory differentiated thyroid cancer [RR-DTC] (cohort F),

• or neuroendocrine gastroenteropancreatic tumors grade 2 and 3

• or Non-small cell lung cancer (cohort H)

• or Solid tumors including soft-tissue sarcoma with immune signature (cohort I), i.e. presence of tertiary lymphoid structures on tumor sample as determined by central review.

• or urothelial cancer (cohort J)

• or HPV-associated cancer (cohort K) with molecular confirmation p16 positive status,

• triple negative breast cancer (cohort L)

• or TMB-high solid tumors (cohort M) with status TMB-high already known

• or MSI-high solid tumors (cohort N) with status MSI-high already known

• or Non clear-cell renal carcinoma (cohort O)

• or Malignant pleural mesothelioma (cohort P).

2. Advanced non resectable / metastatic disease,

3. Patients for which either there is no further established therapy that is known to provide clinical benefit, OR (for patients to be treated with 160 mg regorafenib) regorafenib monotherapy is an approved or established therapeutic option,

4. Age = 18 years,

5. ECOG, Performance status = 1,

6. Measurable disease according to RECIST,

7. Life expectancy > 3 months,

8. Except for cohorts F and H, = 1 previous line (s) of systemic therapy,

9. Adequate hematological, renal, metabolic and hepatic functions:

1. Hemoglobin = 9 g/dl (patients may have received prior red blood cell [RBC] transfusion, if clinically indicated); absolute neutrophil count (ANC) = 1.5 x 109/l and platelet count = 100 x 109/l, lymphocytes = 1000/mm3.

2. Alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartate aminotransferase (ASP) = 2.5 x upper limit of normality (ULN) (= 5 in case of extensive skeletal involvement for AP and/or liver metastasis and = 5 x ULN in case of liver metastasis for AST and ALT).

3. Total bilirubin = 1.5 x ULN.

4. Albumin = 25g/l.

5. Calculated creatinine clearance (CrCl) = 30 ml/min (according to Cockroft and Gault formula).

6. Creatine phosphokinase (CPK) = 2.5 x ULN.

7. INR < 1.5 x ULN

8. aPTT = 1.5 X ULN

9. Lipase = 1.5 X ULN.

10. Cohort specific criteria: Patients with hepatocellular carcinoma must have a correct hepatocellular function, id est Child-Pugh A.

10. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,

11. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy,

12. Recovery to grade = 1 from any adverse event (AE) derived from previous treatment, excluding alopecia of any grade and non-painful peripheral neuropathy grade = 2 (according to the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, version 5.0)),

13. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication,

14. Both women and men must agree to use an highly effective method of contraception throughout the treatment period and for eight weeks after discontinuation of treatment. Acceptable methods for contraception are described in protocol section 7.4.1,

15. Voluntary signed and dated written informed consents prior to any specific study procedure,

16. Patients with a social security in compliance with the French law.

17. Documented disease progression (as per RECIST v1.1) before study entry. For patients of cohort E (STS) and cohort I (Solid-tumors - TLS+): this progression will be confirmed by central review on the basis of two CT scan or MRI obtained not less than 6 months in the period of 12 months prior to inclusion. For patients of cohort F (RR-DTC): this progression will be confirmed by central review on the basis of two CT scan or MRI obtained at less than 12 months prior to inclusion.

18. For patients in cohort H: subjects with histologically or cytologically confirmed diagnosis of non-squamous NSCLC. Documents disease progression based on radiographic imaging, during or after a maximum of 2 lines of systemic treatment for locally/regionally advanced recurrent, Stage IIIb/IV or metastatic disease. Two components of treatments must have been received in the same line or as separate lines of therapy: a maximum of 1 line of platinum-containing chemotherapy regimen, and a maximum of 1 line of PD(L)1 mAb containing regimen. No EGFR, ALK, ROS1 positive tumor mutations. Subjects with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration

19. For patients with urothelial cancer (cohort J):

• A maximum of 1 line of PD(L)1 mAb containing regimen, and

• Patients must have received at least 4 months of PD(L1) mAb treatment.

20. For HPV-associated cancer (cohort K), TMB-high solid tumors (cohort M) MSI-high solid tumors (cohort N), Non clear-cell renal carcinoma (cohort O):

o No previous line of PD(L)1 mAb containing regimen

21. For malignant pleural mesothelioma (Cohort P):

• A maximum of 1 line of PD(L)1 mAb containing regimen, and

• Patients must have received at least 4 months of PD(L1)/ CTLA-4 mAb treatment in the case they received this treatment

22. For triple-negative breast cancer patients (Cohort L)

• A maximum of 1 line of PD(L)1 mAb containing regimen, and

• Patients must have received at least 4 months of PD(L1) mAb treatment

23. For TMB-High cancer patients (Cohort M):

• TMB-High is defined as TMB score > 16 mutations /megabase on tissue or blood sample

Exclusion Criteria:

1. Previous treatment with Avelumab or Regorafenib,

2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways), except for cohort H (NSCLC), Cohort I (Solid tumors (including Soft Tissue Sarcoma) with immune signature (TLS+)) and cohort P (malignant pleural mesothelioma),

3. Evidence of progressive or symptomatic or newly diagnosed central nervous system (CNS) or leptomeningeal metastases,

4. Men or women of childbearing potential who are not using an effective method of contraception as previously described;

5. Participation to a study involving a medical or therapeutic intervention in the last 30 days,

6. Previous enrolment in the present study,

7. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,

8. Known hypersensitivity to any involved study drug or of its formulation components,

9. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent :

1. Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible

2. Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses = 10 mg or 10 mg equivalent prednisone per day

3. Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable

10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,

11. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan or interstitial lung disease with ongoing signs and symptoms at inclusion. History of radiation pneumonitis in the radiation field (fibrosis) is permitted,

12. Has known hepatitis B or hepatitis C, active and/or treated by antiviral therapy

13. Has a known history of Human Immunodeficiency Virus (HIV) (HIV1/2 antibodies) or known acquired immunodeficiency syndrome (AIDS),

14. Spot urine must not show 1+ or more protein in urine or the patient will require a repeat urine analysis,

15. Major surgical procedure or significant traumatic injury within 28 days before start of study medication,

16. Non-healing wound, non-healing ulcer, or non-healing bone fracture requiring orthopedic treatment,

17. Patients with evidence or history of any bleeding diathesis, irrespective of severity,

18. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of study medication,

19. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication),

20. Ongoing infection > Grade 2 as per NCI CTCAE v5.0,

21. Uncontrolled hypertension (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management,

22. Congestive heart failure = New York Heart Association (NHYA) class 2,

23. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months),

24. Myocardial infarction less than 6 months bedfore start of study drug,

25. Uncontrolled cardiac arrhythmias,

26. Pregnant or breast-feeding patients,

27. Individuals deprived of liberty or placed under legal guardianship,

28. Prior organ transplantation, including allogeneic stem-cell transplantation,

29. Known alcohol or drug abuse,

30. Vaccination within 4 weeks of the first dose of Avelumab and while on trial is prohibited except for administration of inactivated vaccines,

31. Patients with any condition that impairs their ability to swallow and retain tablets,

32. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study,

33. Patient with oral anticoagulation therapy,

34. Suspected or known intraabdominal fistula.

35. For cohort H: received more than 2 prior lines of therapy for NSCLC, including subjects with BRAF molecular alteration and subjects with knwon EGFR/ALK/ROS1 molecular alterations are excluded

Related Conditions & MeSH terms

• Biliary Tract Cancer
• Biliary Tract Neoplasms
• Carcinoma
• Carcinoma, Hepatocellular
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Renal Cell
• Colorectal Cancer Not MSI-H or MMR-deficient
• Colorectal Neoplasms
• Gastro-enteropancreatic Neuroendocrine Tumor
• GIST
• Hepatocellular Carcinoma
• HPV-Related Carcinoma
• Kidney Neoplasms
• Mesothelioma
• Mesothelioma, Malignant
• Mesotheliomas Pleural
• Neoplasms
• Neuroendocrine Tumors
• Non-small Cell Lung Cancer
• Oesophageal or Gastric Carcinoma
• Renal Carcinoma
• Sarcoma
• Soft-tissue Sarcoma
• Solid Tumor, Adult
• Stomach Neoplasms
• Thyroid Cancer
• Thyroid Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms
• Urothelial Carcinoma

Intervention

Drug:
• Phase 1 : Regorafenib
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
• Phase 1 : Avelumab
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
• Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
• Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
• Phase 2: low-dose Regorafenib
Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day

Locations

Country	Name	City	State
France	Institut Bergonié	Bordeaux
France	Centre Hospitalier Régional Universitaire - CHU Morvan	Brest
France	Centre Léon Bérard	Lyon
France	Institut de Cancérologie de Montpellier	Montpellier
France	Institut Curie	Paris
France	IUCT Oncopôle - Institut Claudius Regaud	Toulouse
France	Institut Gustave Roussy	Villejuif

Sponsors (3)

Lead Sponsor	Collaborator
Institut Bergonié	Bayer, Merck KGaA, Darmstadt, Germany

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PHASE I : Recommended phase II dose (RP2D)	Recommended phase II dose (RP2D) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.	During the first cycle (28 days)
Primary	PHASE II (7cohorts A, C, D, E, F and G) : Assessment of the antitumor activity of regorafenib	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on objective response under treatment defined as CR or PR following RECIST v1.1 criteria.	Throughout the treatment period, an average of 6 months
Primary	Phase II (cohorts B, H, I, M, N, O and P): Assessment of the antitumor activity of regorafenib	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on 6-month progression-free rate, defined as CR, PR and SD following RECIST v1.1 criteria.	6 months
Primary	Phase II (cohort A'): Assessment of the antitumor activity of regorafenib	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on 4-months progression-free rate, defined as CR, PR and SD following RECIST v1.1 criteria.	4 months
Secondary	PHASE I : Maximum Tolerated Dose (MTD)	Maximum Tolerated Dose (MTD) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.	During the first cycle (28 days)
Secondary	PHASE I : Dose Limiting Toxicities (DLT)	Dose Limiting Toxicities (DLT) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.	During the first cycle (28 days)
Secondary	PHASE I : Toxicity	Toxicity graded using the common toxicity criteria from the NCI v5.	Throughout the treatment period, an average of 6 months
Secondary	PHASE I : Assessment of the antitumor activity of regorafenib - Best overall response	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of best overall response as per RECIST v1.1.	Throughout the treatment period, an average of 6 months
Secondary	PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate under treatment	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of objective response rate under treatment (ORR) defined as CR or PR as per RECIST v1.1.	Throughout the treatment period, an average of 6 months
Secondary	PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of objective response rate at 6-months (ORR) defined as CR or PR as per RECIST v1.1.	Throughout the treatment period, an average of 6 months
Secondary	PHASE I :Assessment of the antitumor activity of regorafenib - non-progression	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 6-months non-progression defined as CR, PR or SD as per RECIST v1.1	6 months
Secondary	PHASE I :Assessment of the antitumor activity of regorafenib - progression-free survival (PFS)	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year progression-free survival (PFS) as per RECIST v1.1.	1 year
Secondary	PHASE I : Assessment of the antitumor activity of regorafenib - overall survival (OS)	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year overall survival (OS) as per RECIST v1.1.	1 year
Secondary	PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC)	PK measurement expressed as Area Under Curve (AUC) for regorafenib.	Day 15 of cycle 1 (Each cycle is 28 days)
Secondary	PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC)	PK measurement expressed as Area Under Curve (AUC) for regorafenib.	Day 1 of cycle 2 (Each cycle is 28 days)
Secondary	PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC)	PK measurement expressed as Area Under Curve (AUC) for regorafenib.	Day 15 of cycle 2 (Each cycle is 28 days)
Secondary	PHASE I :Pharmacocinetics (PK) - half-life for regorafenib.	PK measurement expressed as half-life for regorafenib.	Day 15 of cycle 1 (Each cycle is 28 days)
Secondary	PHASE I :Pharmacocinetics (PK) - half-life for regorafenib.	PK measurement expressed as half-life for regorafenib.	Day 1 of cycle 2 (Each cycle is 28 days)
Secondary	PHASE I :Pharmacocinetics (PK) - half-life for regorafenib.	PK measurement expressed as half-life for regorafenib.	Day 15 of cycle 2 (Each cycle is 28 days)
Secondary	PHASE I :PK - concentration peak for regorafenib.	PK measurement expressed as concentration peak for regorafenib	Day 15 of cycle 1 (Each cycle is 28 days)
Secondary	PHASE I :PK - concentration peak for regorafenib.	PK measurement expressed as concentration peak for regorafenib	Day 1 of cycle 2 (Each cycle is 28 days)
Secondary	PHASE I :PK - concentration peak for regorafenib.	PK measurement expressed as concentration peak for regorafenib	Day 15 of cycle 2 (Each cycle is 28 days)
Secondary	Phase I: Predictive blood biomarkers analysis (cytokines levels) by ELISA.	levels of angiogenic and immunologic biomarkers in blood	day 1 of cycles 1, 2, 4, 6 and at progression
Secondary	Phase I: Predictive blood biomarkers analysis (lymphocytes) by flow cytmetry.	levels of angiogenic and immunologic biomarkers in blood	day 1 of cycles 1, 2, 4, 6 and at progression
Secondary	Phase I: Predictive tumor growth factor biomarkers analysis by immunohistochemistry.	levels of angiogenic and immunologic biomarkers in tissue	day 1 of cycle 1 and day 1 of cycle 2
Secondary	Phase I: Adverses events graded using the common toxicity criteria from the NCI v5 to determine the safety profile of regorafenib plus avelumab.	Toxicity graded using the common toxicity criteria from the NCI v5.	throughouth the treatment period, an average of 6 months
Secondary	PHASE II : Assessment of the antitumor activity of regorafenib - Best overall response	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of best overall response as per RECIST v1.1.	Throughout the treatment period, an average of 6 months
Secondary	PHASE II : Assessment of the antitumor activity of regorafenib - objective response rate	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of objective response rate at 6-months (ORR) defined as CR or PR as per RECIST v1.1.	Throughout the treatment period, an average of 6 months
Secondary	PHASE II :Assessment of the antitumor activity of regorafenib - non progression	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 6-months non-progression defined as CR, PR or SD as per RECIST v1.1.	6 months
Secondary	PHASE II : Assessment of the antitumor activity of regorafenib - Progression-Free Survival (PFS)	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year progression-free survival (PFS) as per RECIST v1.1.	1 year
Secondary	PHASE II : Assessment of the antitumor activity of regorafenib - Overall Survival	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year overall survival (OS) as per RECIST v1.1.	1 year
Secondary	Phase II: Predictive blood biomarkers analysis (cytokines levels) by ELISA.	levels of angiogenic and immunologic biomarkers in blood	day 1 of cycles 1, 2, 4, 6 and at progression
Secondary	Phase II: Predictive blood biomarkers analysis (lymphocytes) by flow cytometry.	levels of angiogenic and immunologic biomarkers in blood	day 1 of cycles 1, 2, 4, 6 and at progression
Secondary	Phase II: Predictive tumor growth factor biomarkers analysis by immunohistochemistry.	levels of angiogenic and immunologic biomarkers in tissue	day 1 of cycle 1 and day 1 of cycle 2
Secondary	Phase II: Adverses events graded using the common toxicity criteria from the NCI v5 to determine the safety profile of regorafenib plus avelumab	Toxicity graded using the common toxicity criteria from the NCI v5	throughouth the treatment period, an average of 6 months
Secondary	Predictive metabolomic analysis by liquid chromatography-mass spectrometry	Levels of metabolites in blood	day 1 of cycles 1, 2, 4, 6 and at progression
Secondary	Phase II (cohort B): assessment of the antitumor activity of regorafenib	Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on CHOI criteria	throughouth the treatment period, an average of 6 months